BioMarin partners with n‑Lorem to pioneer an antisense oligonucleotide therapy for the newly discovered ReNU syndrome, opening a potential first‑in‑disease pipeline for the rare‑disease genetics leader
Executive summary: BioMarin and n‑Lorem Foundation entered an early research collaboration to develop an investigational antisense oligonucleotide for ReNU syndrome. The partnership targets a disease with no approved therapy and leverages BioMarin’s genetic‑medicines leadership, potentially creating a new revenue stream and advancing ASO‑based rare‑disease treatment.
Who is involved: BioMarin, n‑Lorem Foundation, and the ReNU syndrome patient community.
Likely next: Preclinical studies will commence, with an IND filing anticipated if proof‑of‑concept data are generated, followed by potential clinical trials.
On July 27 2026, BioMarin and the n‑Lorem Foundation announced an early‑stage research collaboration to develop an investigational antisense oligonucleotide (ASO) aimed at the genetic root of ReNU syndrome, a disease first identified in 2024 with no approved treatments. The deal pairs BioMarin’s established genetic‑medicines platform with n‑Lorem’s expertise in designing custom ASOs for ultra‑rare disorders. While no financial terms or timelines were disclosed, the collaboration signals BioMarin’s continued investment in expanding its rare‑disease pipeline beyond existing approvals such as Voxzogo. Success could yield a first‑in‑class medicine and reinforce the company’s position in the ASO therapeutic space.
What's next — scenarios
Strategic Pipeline Validation (55%)
BioMarin successfully diversifies revenue streams and proves technical competency in the highly specialized ASO modality.
- Successful completion of preclinical proof-of-concept studies
- Positive regulatory feedback on Investigational New Drug (IND) filing
Technological Bottleneck (30%)
High R&D burn rate without clinical advancement due to the complexity of ultra-rare genetic delivery.
- Extension of preclinical timelines beyond 18 months
- Public statements regarding delivery mechanism challenges
First-in-Class Breakthrough (15%)
Significant valuation uplift and potential for platform licensing to other rare-disease biotech firms.
- Accelerated Orphan Drug Designation (ODD) grant
- Expansion of the collaboration to include multiple ReNU-related genetic variants
What to watch
- BioMarin Q3/Q4 R&D expenditure reports regarding 'genetic medicine platform expansion'
- N-Lorem Foundation research publication updates on ReNU syndrome genetic pathways (next 90 days)
- FDA/EMA orphan drug designation filings for antisense oligonucleotides (next 6 months)
Timeline
- — BioMarin and n-Lorem Foundation Enter Early Research Collaboration to Develop Potential First-in-Disease Medicine for Newly Identified ReNU Syndrome (PR Newswire)
- — U.S. Food and Drug Administration Accepts BioMarin's Supplemental New Drug Application for Full Approval of VOXZOGO® (vosoritide) for Children With Achondroplasia (PR Newswire)
Analysis — what this means
Sectors affected
- rare disease genetic medicines
- antisense oligonucleotide therapeutics
Historical parallels
- FDA acceptance of BioMarin’s supplemental NDA for Voxzogo (vosoritide) for achondroplasia – July 13 2026
Key entities
Sources
- BioMarin and n-Lorem Foundation Enter Early Research Collaboration to Develop Potential First-in-Disease Medicine for Newly Identified ReNU Syndrome — PR Newswire
- U.S. Food and Drug Administration Accepts BioMarin's Supplemental New Drug Application for Full Approval of VOXZOGO® (vosoritide) for Children With Achondroplasia — PR Newswire